|
Market Closed -
Nasdaq Stockholm
15:30:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.3545 SEK | -5.59% |
|
-16.29% | -57.24% |
| 10-21 | Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study | MT |
| 10-21 | Alzinova selects seven U.S. trial sites ahead of phase IIa study | FW |
Company Valuation: Alzinova AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 101.6 | 89.8 | 135.2 | 308.5 | 86.48 | 112 | - | - |
| Change | - | -11.61% | 50.5% | 128.27% | -71.97% | 29.55% | - | - |
| Enterprise Value (EV) 1 | 73.56 | 89.8 | 113.1 | 293 | 102 | 103 | 108 | 112 |
| Change | - | 22.08% | 25.97% | 159.02% | -65.2% | 1.04% | 4.85% | 3.7% |
| P/E | -13.4x | - | -7.4x | -11.2x | -3.07x | -2.53x | -1.31x | -1.31x |
| PBR | - | - | - | - | 0.71x | 0.62x | 0.55x | 0.48x |
| PEG | - | - | - | 0.5x | 0.2x | 0.1x | -0x | - |
| Capitalization / Revenue | - | - | 501x | - | - | 3.57x | - | 12.1x |
| EV / Revenue | - | - | 419x | - | - | 3.29x | - | 12.1x |
| EV / EBITDA | -9.78x | - | - | -14.4x | -3.98x | -52.8x | -1.02x | -1.06x |
| EV / EBIT | -9.78x | - | -6.85x | -14.4x | -3.98x | -52.8x | -1.02x | -1.06x |
| EV / FCF | -2.71x | - | -3.25x | -7.91x | -2.58x | -1.43x | -0.95x | -0.98x |
| FCF Yield | -36.9% | - | -30.8% | -12.6% | -38.8% | -69.9% | -106% | -102% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.48 | - | -0.41 | -0.31 | -0.27 | -0.14 | -0.27 | -0.27 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | 0.27 | - | - | 31.35 | - | 9.25 |
| EBITDA 1 | -7.519 | - | - | -20.38 | -25.6 | -1.95 | -106 | -106 |
| EBIT 1 | -7.519 | - | -16.52 | -20.38 | -25.6 | -1.95 | -106 | -106 |
| Net income 1 | -7.552 | -13.09 | -16.48 | -20.55 | -26.27 | 1.55 | -84 | -84 |
| Net Debt 1 | -28.04 | - | -22.03 | -15.5 | 15.5 | -9 | -4 | - |
| Reference price 2 | 6.4400 | 2.7700 | 3.0350 | 3.4600 | 0.8290 | 0.3545 | 0.3545 | 0.3545 |
| Nbr of stocks (in thousands) | 15,776 | 32,419 | 44,531 | 89,165 | 104,324 | 316,059 | - | - |
| Announcement Date | 2/24/22 A | 2/23/23 A | 2/28/24 A | 2/27/25 A | 3/25/26 A | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.53x | 3.29x | -52.84x | - | 11.4M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 16.06x | 25.54x | 0.63x | 0.34% | 39.44B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.93x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZ Stock
- Valuation Alzinova AB
Select your edition
All financial news and data tailored to specific country editions
